Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.64 |
| ▸ | DRD2 | P14416 | 6/20 | 0.62 |
| ▸ | DRD3 | P35462 | 6/20 | 0.62 |
| ▸ | DRD4 | P21917 | 2/20 | 0.59 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629921 | 0.94 | CYP19A1 (0.64) | CYP19A1DRD2DRD3DRD4CYP26A1 | |
| SCHEMBL629434 | 0.94 | CYP19A1 (0.64) | CYP19A1DRD2DRD3DRD4CYP26A1 | |
| SCHEMBL8688900 | 0.86 | CYP19A1 (0.60) | CYP19A1DRD2DRD3DRD4CYP26A1 | |
| SCHEMBL3154982 | 0.86 | DRD2 (0.65) | CYP19A1DRD2DRD3DRD4CYP26A1 | |
| SCHEMBL9630417 | 0.86 | CYP19A1 (0.63) | CYP19A1DRD2DRD3DRD4CYP26A1 | |
| SCHEMBL9361478 | 0.86 | DRD2 (0.65) | CYP19A1DRD2DRD3DRD4CYP26A1 | |
| SCHEMBL9361141 | 0.86 | DRD2 (0.65) | CYP19A1DRD2DRD3DRD4CYP26A1 | |
| Hydrochloric Acid SCHEMBL9688676 | 0.84 | DRD2 (0.63) | CYP19A1DRD2DRD3DRD4CYP26A1 | |
| Hydrochloric Acid SCHEMBL9688679 | 0.84 | DRD2 (0.63) | CYP19A1DRD2DRD3DRD4CYP26A1 | |
| Hydrochloric Acid SCHEMBL9688751 | 0.84 | DRD2 (0.63) | CYP19A1DRD2DRD3DRD4CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190717-A1 | P38 GAMMA INHIBITORS AND METHOD OF USE THEREOF | CITY OF HOPE | 2023-06-22 | — | — | US | disclosed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CYP19A1 2255/4885DRD2 4396/4885DRD3 4635/4885 |
| US-20230190717-A1 | P38 GAMMA INHIBITORS AND METHOD OF USE THEREOF | CDC42BPG, MAPK1, MAPK7 | CYP19A1 3269/4885DRD2 4764/4885DRD3 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.